Thematic funds are a type of open ended equity Scheme, investing in companies that are focused on a specific theme/sector.
We are upgrading our transaction portal and will be back soon.
Healthcare is crucial for human life – its availability and affordability have significant impact on society's well-being. In developing countries like India, healthcare services are vital for sustainable economic development. The Indian healthcare market, valued at US$ 110 billion in FY16, is projected to reach US$ 638 billion by FY25, growing at an average of 22% annually (Indian Brand Equity Foundation, February 2025). This sector seeks to offer diverse investment opportunities across the value chain.
Invest in Baroda BNP Paribas Health and Wellness Fund - designed to tap into the long-term growth potential of the Pharma and Healthcare sectors.
Rising Income and Middle-Class Expansion: An ageing population and growing middle class, with increased purchasing power will increase demand for quality healthcare services.
Changes in Demographics: The percentage of population above 45 years of age is projected to rise from 27% in 2023 to 41% in 2050^. The rise in lifestyle-related illnesses along with ageing population has increased need for healthcare services. It is estimated that the incidence of cardiac issues and diabetes would increase by ~34% from 2020 to 2030*.
Government Initiatives and Policy Support: Various government initiatives aim to provide affordable healthcare to millions of people, further driving the growth of the sector.
^Source: UN Department of Economic and Social Affairs - World Population Prospects 2024
*Source: Boston Consulting Group Analysis, Report dated 2024
The scheme seeks to provide investors the opportunity to capitalize on one of the most resilient and high-growth sectors.
Focused on companies expected to benefit from growth in Pharma and Healthcare space
Invest at least 80% of its net assets in companies in Pharma and Healthcare sector, and allied service providers to the sector
Actively managed Scheme, with a bottom-up stock selection approach
Best suited for those looking to hold their investments for over three years to fully benefit from the sector's growth potential
A thematic scheme with no market cap limit or preference
Drug Manufacturers Biotechnology Companies API Manufacturers
Discovery Clinical Development Manufacturing
Multi Specialty Single - Specialty
Pathology Radiology Molecular diagnostics
Fitness and Gyms Assisted Living Centers Nutritional Supplements
Medical Devices Pharmacy Retail Insurance and more...
@ These businesses or services directly or indirectly form part of the Pharma, Healthcare and allied sectors. CROs/CDMOs: Contract Research Organizations and Contract Development and Manufacturing
Organizations
For additional information please refer to the SID
Scheme Name | Baroda BNP Paribas Health and Wellness Fund |
Type of the Scheme | An open ended equity scheme investing in Pharma and Healthcare sector |
Category | Sectoral / Thematic Fund – Pharma and Healthcare Theme |
Investment Objective | The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns. However, there can be no assurance that the investment objective of the Scheme will be realized. |
Benchmark | BSE Healthcare Total Return Index |
Fund Manager~ | Mr. Sanjay Chawla |
Load Structure |
Exit Load: Redemption/ switch out of units upto 10% of the units allotted before 1 year from date of allotment – Exit load – NIL. For redemption/switch out of units above 10% of units allotted within 1 year from the date of allotment: 1.00% of applicable NAV For redemption/switch out of units after 1 year from the date of allotment: Nil. The above load shall also be applicable for switches between the schemes of the Fund and all Systematic Investment Plans, Systematic Transfer Plans, Systematic Withdrawal Plans. No load will be charged on units issued upon re-investment of amount of distribution under same IDCW option and bonus units. There shall be no exit load levied in case of switch of investments i) between the Plans (i.e. Regular and Direct Plans); and/or ii) between the options (i.e. IDCW and Growth options), within the Scheme/Plan. For any change in load structure, the AMC will issue an addendum and display it on the website/ISCs. |
Minimum Application Amount/switch | Lumpsum Details: A minimum of Rs. 1,000 per application and in multiples of Rs.1 thereafter. Systematic Investment Plan: (i) Daily, Weekly, Monthly SIP: Rs. 500/- and in multiples of Re. 1/- thereafter; (ii) Quarterly SIP: Rs. 1500/- and in multiples of Re. 1/- thereafter. |
Minimum Application Amount/switch in |
Lumpsum investment: Rs. 1,000 and in multiples of Rs. 1 thereafter. Systematic Investment Plan: (i) Daily, Weekly, Monthly SIP: Rs. 500/- and in multiples of Re. 1/- thereafter; (ii) Quarterly SIP: Rs. 1500/- and in multiples of Re. 1/- thereafter. There is no upper limit on the amount for application. The Trustee / AMC reserves the right to change the minimum amount for application and the additional amount for application from time to time in the Scheme and these could be different under different plan(s) / option(s). Note – The aforesaid requirement of minimum application shall not be applicable on the mandatory investments made by the Designated Employees of the AMC in accordance with clause 6.10 of SEBI Master Circular on Mutual Funds |
#Please refer to the Scheme Information Document of the scheme before investing for details including investment objective, asset allocation, investment strategy, risk factors and taxation.
KIM and Editable Application Form
Click HereSID
Click HereProduct Presentation
Click HereProduct one pager
Click HereThematic funds are a type of open ended equity Scheme, investing in companies that are focused on a specific theme/sector.
Baroda BNP Paribas Health and Wellness Fund is an equity oriented thematic fund which invests predominantly in companies in the Pharma and Healthcare sector. The investment objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns. However, there can be no assurance that the investment objective of the Scheme will be realized.
Healthcare is a long-term structural growth story, with diversification in terms of industries available for investment. A couple of reasons driving growth in this theme are as follows:
Stock | Weights |
---|---|
Sun Pharmaceutical Industries | 15.64% |
Cipla Ltd. | 6.94% |
Max Healthcare Institute Limit | 6.41% |
Divis Laboratories Ltd. | 6.14% |
Dr.Reddys Laboratories Ltd. | 5.70% |
Apollo Hospitals Enterprise Ltd. | 5.55% |
Lupin Ltd. | 4.01% |
Fortis Healthcare Ltd. | 2.83% |
Torrent Pharmaceuticals Ltd. | 2.75% |
Aurobindo Pharma Ltd. | 2.71% |
Source: BSE Indices, Data as on April 30, 2025.
Source: MFI Explorer, Data as of April 30, 2025. Returns are Compounded Annualized. Past performance may or may not be sustained in future and is not a guarantee of any future returns.
Type of Instrument | Minimum (% of Net Assets) | Maximum (% of Net Assets) |
---|---|---|
Equity & equity^ related instruments of companies in the Pharma & Healthcare# and allied sectors | 80 | 100 |
Other Equity and equity related^ instruments of companies other than above | 0 | 20 |
Debt & Money Market instruments* | 0 | 20 |
Units of Mutual Funds (Domestic Schemes) | 0 | 10 |
Units issued by REITs & INvITs | 0 | 10 |
# Pharma and Healthcare Sector companies include:
The above list is only indicative, and the Scheme will look to invest in new and emerging areas of Pharma and Healthcare sector which shall be appropriate for the theme of the Scheme.
^The Scheme may invest up to 50% of equity assets in equity derivatives instruments as permitted under the SEBI (Mutual Funds) Regulations, 1996 from time to time. The Scheme may use equity derivatives for such purposes as maybe permitted under the SEBI (Mutual Funds) Regulations, 1996, including but not limited for the purpose of hedging and portfolio balancing, based on the opportunities available and subject to guidelines issued by SEBI from time to time.
*Debt instruments may include securitised debt up to 20% of the debt portfolio of the scheme. Money Market instruments include commercial papers, commercial bills, treasury bills, Government securities having an unexpired maturity up to one year, call or notice money, certificate of deposit, usance bills, and any other like instruments as specified by the Reserve Bank of India from time to time.
For detailed asset allocation, please refer to SID on our website www.barodabnpparibasmf.in
We suggest investors should consult their financial advisor before investing.
This Scheme is suitable for:
We suggest investors should consult their financial advisor before investing.
Given that healthcare is a long-term theme, it would be preferable for an investor to stay invested in the fund for upwards of 3 years and seek to reap benefits from the growth in this sector.
We suggest investors should consult their financial advisor before investing.
In the preparation of the material contained in this document, Baroda BNP Paribas Asset Management India Ltd. (“AMC”) has used information that is publicly available, including information developed in-house. The AMC, however, does not warrant the accuracy, reasonableness and/or completeness of any information. This document may contain statements/opinions/ recommendations, which contain words, or phrases such as “expect”, “believe” and similar expressions or variations of such expressions that are “forward looking statements”. Actual results may differ materially from those suggested by the forward looking statements due to risk or uncertainties associated with our expectations with respect to, but not limited to, exposure to market risks, general economic and political conditions in India and other countries globally, which have an impact on our investments, the monetary and interest policies of India, inflation, deflation, unanticipated turbulence in interest rates, foreign exchange rates, equity prices or other rates or prices, etc. The AMC (including its affiliates), Baroda BNP Paribas Mutual Fund (“Mutual Fund”), its sponsor / trustee and any of its officers, directors, personnel and employees, shall not be liable for any loss, damage of any nature, including but not limited to direct, indirect, punitive, special, exemplary, consequential, as also any loss of profit in any way arising from the use of this document in any manner. The recipient alone shall be fully responsible / liable for any decision taken based on this document. All figures and other data given in this document are dated and may or may not be relevant at a future date. Prospective investors are therefore advised to consult their own legal, tax and financial advisors to determine possible tax, legal and other financial implication or consequence of subscribing to the units of the schemes of Baroda BNP Paribas Mutual Fund . Past performance may or may not be sustained in the future. Please refer to the Scheme Information Document of the schemes before investing for details of the scheme including investment objective, asset allocation pattern, investment strategy, risk factors and taxation.
In the preparation of this document, Baroda BNP Paribas Asset Management India Ltd. (“AMC”) has used information that is publicly available and developed in-house. The AMC, however, does not warrant the accuracy, reasonableness and/or completeness of any information. This document may contain statements/opinions/ recommendations, which contain words, such as “expect”, “believe” and similar expressions or variations that are “forward looking statements”. Actual results may differ materially from those suggested by the forward looking statements due to risk or uncertainties associated with our expectations with respect to, but not limited to, exposure to market risks, general economic and political conditions in India and other countries globally, which have an impact on our investments, the monetary and interest policies of India, inflation, deflation, unanticipated turbulence in interest rates, foreign exchange rates, equity prices or other rates or prices, etc. The AMC (including its affiliates), Baroda BNP Paribas Mutual Fund (“Mutual Fund”), its sponsor / trustee and any of its officers, directors, employees, shall not liable for any loss, damage of any nature, including direct, indirect, punitive, exemplary, consequential, or loss of profit arising from use of this document. The recipient alone shall be fully responsible for decision taken based on this document. All data given in this document is dated and may or may not be relevant at a future date. Investors are advised to consult their legal/tax/financial advisors to determine possible tax, legal and other financial implication or consequences of investing into the scheme. Past performance may or may not be sustained in the future.